MK-8892

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Left Heart DiseasePulmonary Arterial HypertensionPulmonary Hypertension

Phase 1

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

CompletedNCT01798849

Merck Sharp & Dohme LLCPulmonary Arterial Hypertension

Start: 2013-03-15End: 2013-07-17Updated: 2019-07-22

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

CompletedNCT01926509

Merck Sharp & Dohme LLCPulmonary Arterial Hypertension

Start: 2013-11-14End: 2014-09-08Updated: 2018-12-03

Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

TerminatedNCT01934647

Merck Sharp & Dohme LLCPulmonary Arterial Hypertension

Start: 2013-11-22End: 2014-09-08Updated: 2018-10-22

A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)

TerminatedNCT02078557

Merck Sharp & Dohme LLCLeft Heart Disease, Pulmonary Hypertension

Start: 2014-05-09End: 2014-09-10Updated: 2018-10-31